No products in the cart.
Duloxetine is effective in refractory chronic cough
1. Duloxetine is significantly more effective than placebo at reducing refractory chronic cough (RCC) frequency and sensitivity. Evidence Rating Level:...
Pharma
AstraZeneca moves to own multimodal oncology AI with Modella
1. AstraZeneca is acquiring Modella AI to embed multimodal foundation models into oncology R&D and strengthen biomarker driven trial strategy....
NVIDIA and Lilly put $1B behind AI as core drug infrastructure
1. NVIDIA and Eli Lilly plan to invest up to $1B over five years in a joint AI lab to...
Berberine is safe and effective in lowering lipoprotein cholesterol levels in metabolic dysfunction-associated steatotic liver disease
1. In diabetes-free individuals with metabolic dysfunction–associated steatotic liver disease (MASLD) and obesity, berberine is safe, well-tolerated, and associated with...
![2MM: AI Roundup- AI Cancer Test, Smarter Hospitals, Faster Drug Discovery, and Mental Health Tech [May 2nd, 2025]](data:image/svg+xml;nitro-empty-id=NzY5OjExNjQ=-1;base64,PHN2ZyB2aWV3Qm94PSIwIDAgMSAxIiB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==)
2MM: AI Roundup – Lilly and NVIDIA’s $1B AI lab, Illumina’s Billion Cell Atlas, AstraZeneca’s Modella deal, and Claude for Healthcare [Jan 19th, 2026]
NVIDIA and Lilly put $1B behind AI as core drug infrastructure During the JPMorgan Healthcare Conference week in mid January...
Ethosuximide may not be effective for the treatment of abdominal pain in irritable bowel syndrome
1. Ethosuximide was not superior to placebo for the treatment of abdominal pain in adults with irritable bowel syndrome. Evidence...
Edaravone dexborneol improves functional independence in patients with acute ischaemic stroke following endovascular thrombectomy
1. Compared to placebo, edaravone dexborneol improved functional independence at 90 days in patients with acute ischaemic stroke who underwent...
![Engineered stem cells mitigate liver damage caused by radiation [PreClinical]](data:image/svg+xml;nitro-empty-id=ODExOjEzMTI=-1;base64,PHN2ZyB2aWV3Qm94PSIwIDAgMSAxIiB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==)
Yartemlea (narsoplimab-wuug) improves platelets hemolysis organ function hematopoietic stem cell transplant–associated thrombotic microangiopathy transplant patients
1. Yartemlea (narsoplimab-wuug) is the first on‑label complement inhibitor for hematopoietic stem cell transplant (HSCT) associated thrombotic microangiopathy, associated with improvements...
FDA highlights flexible chemistry manufacturing controls expectations for cell and gene therapies
1. New FDA communication introduces a more flexible, risk‑based chemistry, manufacturing, and controls (CMC) framework for cell and gene therapies,...
Nuzolvence (Zoliflodacin) first oral Gonorrhea treatment shows non-inferior cure rates
1. Nuzolvence (zoliflodacin) is the first single‑dose oral agent for uncomplicated urogenital gonorrhea, showing non‑inferior cure rates to ceftriaxone‑based therapy...
